VIDEO: US specialist sympathizes with EU colleagues over EMA rejection of pegcetacoplan
Click Here to Manage Email Alerts
BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Baruch D. Kuppermann, MD, PhD, comments on the decision of the European Medicines Agency to reject the appeal for the approval of pegcetacoplan.
He sympathizes with the disappointment of his European colleagues who have been denied access to a pharmacotherapy that can benefit patients with geographic atrophy.
Like most retina specialists in the U.S., Kuppermann uses both Syfovre (pegcetacoplan injection, Apellis Pharmaceuticals) and Izervay (avacincaptad pegol intravitreal solution, Astellas Pharma), but he noted that some have chosen not to prescribe them because of what they perceive as a modest benefit and some aspects of risk.
“The EMA result is not completely out of character or out of reason, but it is a disappointment because it’s nice to have at least some options available to our patients,” he said.
Collapse
Healio Interviews
Read more about
Click Here to Manage Email Alerts